文献速递细胞病理与分子病理

心包积液细胞病理学TIS报告系统应用的系统评价与荟萃分析

Navigating the International System for Reporting Serous Fluid Cytopathology in pericardial effusion: A meta-analysis.
PubMed 文献 · Cancer Cytopathol · 2026-01-01

该研究系统检索2013至2023年PubMed文献,纳入10项应用TIS分类心包积液细胞学的研究共2976例样本。荟萃分析显示各TIS类别恶性风险呈梯度上升,非诊断性10.8%、良性8.7%、非典型34.0%、可疑恶性64.1%、恶性78.6%,支持TIS对心包积液的恶性风险分层价值,但良性与恶性类别存在显著异质性。

要点

  • 心包积液TIS各分类恶性风险呈递增趋势,支持其诊断分层效用
  • 恶性类别占比23.4%,可疑恶性与恶性类别恶性风险分别达64.1%和78.6%
  • 良性与恶性类别异质性显著,需标准化报告与前瞻性验证

核心结论

  • TIS可有效对心包积液细胞学样本进行恶性风险分层,各类别恶性风险呈递增趋势支持其诊断效用。
  • 良性与恶性类别存在显著异质性,提示需标准化报告并进一步前瞻性验证TIS。

研究设计与样本

  • 系统评价与荟萃分析,遵循PRISMA指南,检索PubMed 2013至2023年文献。
  • 纳入10项应用TIS分类心包积液细胞学的研究,共2976例心包积液样本。
  • 排除病例报告、病例回顾、摘要、比较研究、非英文发表及未按TIS分类心包积液样本的研究。

主要发现

  • TIS类别汇总分布:非诊断性2.9%、良性60.2%、非典型5.4%、可疑恶性2.4%、恶性23.4%。
  • 基于组织学确认的恶性风险:非诊断性10.8%、良性8.7%、非典型34.0%、可疑恶性64.1%、恶性78.6%。

关键数值与推荐

  • TIS将浆液性体液细胞学分为五类:非诊断性、良性、非典型、可疑恶性、恶性。
  • 心包积液各TIS类别恶性风险:非诊断性10.8%、良性8.7%、非典型34.0%、可疑恶性64.1%、恶性78.6%。

临床怎么用

  • 心包积液细胞学报告可采用TIS五分类框架,并参照各类别恶性风险辅助临床决策。
  • 对非典型、可疑恶性及恶性类别应结合组织学确认,注意良性类别也存在一定恶性风险。

局限性

  • 良性与恶性类别存在显著异质性。
  • 需标准化报告并进一步前瞻性验证TIS在心包积液中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The International System for Reporting Serous Fluid Cytopathology (TIS) provides a standardized framework for classifying serous fluid cytology into five diagnostic categories: nondiagnostic, negative for malignancy, atypical, suspicious for malignancy, and malignant. Although TIS has been widely adopted for pleural and peritoneal fluids, its application in pericardial effusion cytology remains limited. The objective of this study was to evaluate the use of TIS in pericardial effusion samples and estimate the associated risk of malignancy for each category. METHODS: A systematic review was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Studies published between 2013 and 2023 were identified through a comprehensive PubMed search. Eligible studies applied TIS to pericardial effusion cytology. The analysis excluded case reports, case reviews, abstracts, comparative studies, and non-English publications. Furthermore, the authors omitted studies that did not explicitly categorize pericardial fluid samples using the TIS categorization. Ten studies met inclusion criteria, comprising 2976 pericardial fluid samples. RESULTS: The pooled distribution across TIS categories were: nondiagnostic (2.9%), negative for malignancy (60.2%), atypical (5.4%), suspicious for malignancy (2.4%), and malignant (23.4%). Risk of malignancy estimates based on histologic confirmation were: 10.8% for nondiagnostic, 8.7% for negative for malignancy, 34.0% for atypical, 64.1% for suspicious for malignancy, and 78.6% for malignant categories. CONCLUSIONS: TIS effectively stratifies pericardial effusion cytology samples by malignancy risk. The progressive increase in the risk of malignancy across categories supports its diagnostic utility. However, substantial heterogeneity, particularly in the negative for malignancy and malignant categories, highlights the need for standardized reporting and further prospective validation of TIS.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Arshia A, Kalfert D, Kholová I, et al. Navigating the International System for Reporting Serous Fluid Cytopathology in pericardial effusion: A meta-analysis. Cancer Cytopathol. 2026. PMID: 41854368. doi:10.1002/cncy.70091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。